- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06459245
Resistance Training to Prevent Lymphedema After Breast Cancer Surgery Randomized Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Peking University First Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
It was first diagnosed as grade I to III unilateral breast cancer by pathological examination; Breast cancer surgery was completed and axillary lymph node dissection was performed; To receive postoperative adjuvant treatment and follow-up in the outer fourth ward; Be able to communicate and exchange normally; Volunteer to participate in this research
Exclusion Criteria:
Extreme fatigue, severe anemia, ataxia, etc.; The presence of upper limb or shoulder problems from breast cancer treatment; Edema is in a non-stable stage (stable stage of edema means no treatment for edema in the past 3 months; No inflammation of the upper extremities requiring anti-infective treatment; No change in daily activities; Limb circumference change < 10%) ; Limited limb movement due to trauma, shoulder periarthritis, etc.; Limb braking is required for health reasons. Patients are lost to follow-up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Routine rehabilitation training
Starting from the first day after surgery, progressive progress was carried out according to the functional exercise table of the affected limb in the ward Functional exercise of affected limb; Pneumatic pressure pump physiotherapy during hospitalization: once a day, 30min each time;
|
|
Experimental: Resistance training
Bend the dumbbell, hold a dumbbell in each hand, put it on the side of the body, bend the arm to lift the dumbbell, the front wall and the upper arm as close as possible; Hold the dumbbells flat on the side, with the back straight, stand with feet, arms perpendicular to the side of the body, hold the dumbbells with both hands, and lift the dumbbells to the side above shoulder level, elbows slightly bent; Stand with your feet straight, hold the dumbbells, and extend your arms back as far as possible.
You can feel your upper arms and lower back being stretched.
With your feet open, hold the dumbbells with both hands and extend your arms naturally in front of you.
Lift them up until your elbows are above shoulder height and hold for 1-2 seconds.The training frequency is 2 to 3 times a week, 2 to 3 sets each time
|
Bend the dumbbell, holding one dumbbell in each hand, on the side of the body, bend the arm to lift the dumbbell, front wall and upper arm as close as possible, pause for a moment, and then slowly lower the dumbbell until both arms are completely straight The second section of the dumbbell side flat, straight back, feet standing, arms perpendicular to the side of the body, hands grasp the dumbbell, to the side above the shoulder level, elbow slightly bent, and then put back in place The third section of the dumbbell rowing, feet stand straight, hold the dumbbell, the arm as far back as possible, can feel the upper arm and the waist back is stretched, and then straight back into the preparatory position Section 4: Lift the dumbbell flat in front of you, with your feet open, hold the dumbbell with both hands, extend your arms naturally in front of you, lift the dumbbell to the elbow above shoulder height, stay for 1-2 seconds.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lymphedema occurrence
Time Frame: 3 months after intervention
|
Tissue and local edema due to obstruction of lymphatic drainage
|
3 months after intervention
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023SF23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Adrienne G. WaksGilead SciencesRecruitingBreast Cancer Female | Breast Cancer Metastatic | Her 2 Positive Breast CancerUnited States
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
Institut fuer FrauengesundheitSamsung Bioepis Co., Ltd.RecruitingBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer FemaleGermany
-
Wake Forest University Health SciencesAtrium Health NavicentActive, not recruitingBreast Cancer Female | Early-stage Breast CancerUnited States
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
PfizerActive, not recruitingHR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast CancerUnited States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
Clinical Trials on Resistance training
-
University of KasselCompleted
-
University of KasselUniversity of PotsdamCompleted
-
University of Alabama at BirminghamCompletedMusculoskeletal and Metabolic CrosstalkUnited States
-
University of Applied Sciences of Western SwitzerlandCompleted
-
University of BarcelonaCompleted
-
Vienna Hospital AssociationCompleted
-
Universidade Federal do Triangulo MineiroUnknown
-
Universidade Federal de Sao CarlosConselho Nacional de Desenvolvimento Científico e TecnológicoCompletedChronic Obstructive Pulmonary DiseaseBrazil
-
Hong Kong Metropolitan UniversityRecruitingFrailty | Mood | Cognition | Mobility | SacropeniaHong Kong
-
Riphah International UniversityRecruitingCoronary Artery DiseasePakistan